Association of ovarian tumor epithelium coexpressing HLA-DR and CA-125 antigens with tumor infiltrating cytotoxic T lymphocytes

Journal of Nippon Medical School

Volumn 70, Issue 1, 2003, Pages 40-44

  Matsushita, Norihiro ^a   Ghazizadeh, Mohammad ^a   Konishi, Hideki ^a   Araki, Tsutomu ^a  

^a NIPPON MEDICAL SCHOOL   (Japan)

Author keywords

Antigens; CA 125; CD 8; HLA DR; Ovarian tumor; TILs; Tumor infiltrating cytotoxic T lymphocytes

Indexed keywords

CA 125 ANTIGEN; HLA DR ANTIGEN;

ANTIGEN EXPRESSION; ARTICLE; CANCER CLASSIFICATION; CANCER MORTALITY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DISEASE ASSOCIATION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; OVARY CARCINOMA; PROGNOSIS; TUMOR ASSOCIATED LEUKOCYTE;

EID: 0344406265     PISSN: 13454676     EISSN: None     Source Type: Journal    
DOI: 10.1272/jnms.70.40     Document Type: Article

References (16)

1. Bodmer J, and Bodmer W: Histocompatibility 1984. Immunol Today 1984; 5: 251-254.
2. Anderse SN, Rognum TO, Lund E, Meling GI, Hauge S: Strong HLA-DR expression in large bowel carcinomas is associated with good prognosis. Br J Cancer 1993; 68: 80-85.
3. Kunihiro M, Tanaka S, Haruma K, Yoshihara M, Sumii K, Kajiyama G, Shimamoto F: Combined expression of HLA-DR antigen and proliferating cell nuclear antigen correlate with colorectal cancer prognosis. Oncology 1998; 55: 326-333.
4. Cooper BC, Sood AK, Davis CS, Ritchie JM, Sorosky JI, Anderson B, Buller RE: Preoperative CA 125 levels: an independent prognostic factor for epithelial ovarian cancer. Obstet Gynecol 2002; 100: 59-64.
5. Peters-Engl C, Obermair A, Heinzl H, Buxbaum P, Sevelda P, Medl M: CA 125 regression after two completed cycles of chemotherapy: lack of prediction for long-term survival in patients with advanced ovarian cancer. Br J Cancer 1999; 81: 662-666.
6. Marth C, Fuith LC, Bock G, Daxenbichler G, Dapunt O: Modulation of ovarian carcinoma tumor marker CA-125 by gamma-interferon. Cancer Res 1989; 49: 6538-6542.
7. Marth C, Widschwendter M, Kaern J, Jorgensen NP, Windbichler G, Zeimet AG, Trope C, Daxenbichler G: Cisplatin resistance is associated with reduced interferon-gamma-sensitivity and increased HER-2 expression in cultured ovarian carcinoma cells. Br J Cancer 1997; 76: 1328-1332.
8. Scully, R.E: Histological typing of ovarian tumors, 2 nd ed. Springer-Verlag, Berlin, 1999.
9. Peterson F: Annual Report on Gynecological Cancer of FIGO, vol. 20, Panorama Press, Stockholm 1988.
10. Ghazizadeh M, Ogawa H, Sasaki Y, Araki T, Aihara K: Mucin carbohydrate antigens (T, Tn, and sialyl-Tn) in human ovarian carcinoma: Relationship with histopathology and prognosis. Hum Pathol 1997; 28: 960-966.
11. Ottenhoff TH, Elferink DG, Hermans J, de Vries RR: HLA class II restriction repertoire of antigen-specific T cells. I. The main restriction determinants for antigen presentation are associated with HLA-D/DR and not with DP and DQ. Hum Immunol 1985; 13: 105-16.
12. Andersen SN, Rognum TO, Lund E, Meling GI, Hauge S: Strong HLA-DR expression in large bowel carcinomas is associated with good prognosis. Br J Cancer 1993; 68: 80-85.
13. Shikorska B, Danilewics M, Wagrowska-Danilewics M: HLA-DR expression is a significant prognostic factor in laryngeal cancer. A morphometric analysis. APMIS 1999; 107: 383-388.
14. Schumacher K, Haensch W, Roefzaad C, Schlag PM: Prognostic significance of activated CD 8 (+) T cell infiltrations within esophageal carcinomas. Cancer Res 2001; 61: 3932-3936.
15. Dadmarz RD, Ordoubadi A, Mixon A, Thompson CO, Barracchini KC, Hijazi YM, Steller MA, Rosenberg SA, Scwartzentruber DJ: Tumor-infiltrating lymphocytes from human ovarian cancer patients recognize autologous tumor in an MHC Class II-restricted fashion Cancer J Sci Am 1996; 2: 263-267.
16. Kooi S, Zhang HZ, Patenia R, Edwards CL, Platsoucas CD, Freedman RS: HLA class I expression on human ovarian carcinoma cells correlates with T-cell infiltration in vivo and T-cell expansion in vitro in low concentrations of recombinant interleukin-2. Cell Imunol 1996; 174: 116-128.